Your present location:Home

Company Overview

Founded in August 2014, Shenzhen TargetRx, Inc. is a Sino-American joint venture, high-tech pharmaceutical research and development company. When established, company won the investment from famous angel institutions in China with a registered capital of RMB 80 million. The company focuses on the research and development of targeted drugs, and aims to become the world’s leading research and development platform for targeted drugs. Company founder, Dr. Yihan Wang graduated from New York University, is an internationally well-known medical expert, leader of overseas Chinese, and Shenzhen Peacock Plan B talent. He has over 16 years of oversea working experience in the field of small molecule targeted anti-cancer drugs, and is the key inventor of international forefront drugs, such as IClusig (Ponatinib), Alunbrig (Brigatinib), and Ridaforolimus. Dr. Wang has 27 authorized invention patents, and has published more than 60 papers. Headed by Dr. Wang, Shenzhen TargetRx, has devoted itself to the research and development of anti-tumor drugs and saving the life of cancer patients.

With the global desideration of novel small molecule targeted anti-tumor drugs, Shenzhen TargetRx designs, screens, evaluates, optimizes, and researches original series of the 3rd generation small molecule anti-tumor drugs that have independent intellectual property rights. By doing so, Shenzhen TargetRx works to overcome the difficulty – acquired drug resistance, and strives to turn cancer from the No. 1 killer of human lives into chronic disease.

About R&D Pipeline News Partners Careers Contact

Rm 301, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China

Copyright Shenzhen TargetRx, Inc.Powered by:www.300.cnshenzhen 粤ICP备17142950号

Follow us